NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.
Taylor BC, Sun X, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Wescott EC, Opalenik SR, Hanna A, Chou ST, Van Kaer L, Gomez H, Isaacs C, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Pietenpol JA, Balko JM.
Taylor BC, et al. Among authors: pietenpol ja.
Cancer Discov. 2024 Feb 8;14(2):290-307. doi: 10.1158/2159-8290.CD-23-0519.
Cancer Discov. 2024.
PMID: 37791898
Free PMC article.